购物车
- 全部删除
- 您的购物车当前为空
Cgp 6809 is a new methylnitrosoureido-sugar derivative that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.
Cgp 6809 is a new methylnitrosoureido-sugar derivative that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 15,000 | 8-10周 | |
50 mg | ¥ 19,800 | 8-10周 | |
100 mg | ¥ 25,500 | 8-10周 |
产品描述 | Cgp 6809 is a new methylnitrosoureido-sugar derivative that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer. |
别名 | Cgp-6809, Cgp6809 |
分子量 | 321.33 |
分子式 | C12H23N3O7 |
CAS No. | 84069-38-5 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容